These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23528442)

  • 21. Antiepileptic drugs with mood stabilizing properties and their relation with psychotropic drug use in institutionalized epilepsy patients with intellectual disability.
    Leunissen CL; de la Parra NM; Tan IY; Rentmeester TW; Vader CI; Veendrick-Meekes MJ; Aldenkamp AP
    Res Dev Disabil; 2011; 32(6):2660-8. PubMed ID: 21752594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: an overview.
    Matson JL; Neal D
    Res Dev Disabil; 2009; 30(3):572-86. PubMed ID: 18845418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Psychotropic drugs and the risk of arrhythmias].
    Toivonen L
    Duodecim; 2002; 118(12):1223-4. PubMed ID: 12239813
    [No Abstract]   [Full Text] [Related]  

  • 24. [Psychotropic drug prescription to people with intellectual disability in GP practices].
    Bakker-van Gijssel EJ; Leusink GL
    Ned Tijdschr Geneeskd; 2015; 159():A9754. PubMed ID: 26629605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Use of psychotropic drugs in children, adolescents and subjects with intellectual disability: a review].
    Lazzeretti L; Pracucci C; Benni L; Godini L; Talamba GA; Faravelli C
    Riv Psichiatr; 2011; 46(1):1-17. PubMed ID: 21446107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in the residential (inpatient) treatment of individuals with a dual diagnosis.
    Spreat S; Behar D
    J Consult Clin Psychol; 1994 Feb; 62(1):43-8. PubMed ID: 7913478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The association between severity of intellectual disability and psychiatric symptomatology.
    Holden B; Gitlesen JP
    J Intellect Disabil Res; 2004 Sep; 48(Pt 6):556-62. PubMed ID: 15312056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychotropic medication for behaviour problems in people with intellectual disability: a review of the current literature.
    Deb S; Unwin GL
    Curr Opin Psychiatry; 2007 Sep; 20(5):461-6. PubMed ID: 17762588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychologists and psychoactive drugs.
    Murray JB
    Genet Psychol Monogr; 1978 Nov; 98(Second Half):281-323. PubMed ID: 31317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Determinants of psychotropic medication in adults with mild or moderate intellectual disabilities].
    Schützwohl M; Voss E; Stiawa M; Salize HJ; Puschner B; Koch A
    Nervenarzt; 2017 Nov; 88(11):1273-1280. PubMed ID: 27638741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychopharmacotherapy in children and adults with intellectual disability.
    Santosh PJ; Baird G
    Lancet; 1999 Jul; 354(9174):233-42. PubMed ID: 10421318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program.
    Lange-Asschenfeldt C; Grohmann R; Lange-Asschenfeldt B; Engel RR; Rüther E; Cordes J
    J Clin Psychiatry; 2009 Sep; 70(9):1258-65. PubMed ID: 19538904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Unwanted drug effects of psychotropic drugs in neurologic practice].
    Schmidt LG; Schüssler G; Linden M; Müller-Oerlinghausen B
    Nervenarzt; 1985 Jan; 56(1):19-24. PubMed ID: 2858064
    [No Abstract]   [Full Text] [Related]  

  • 34. Comorbidity in psychiatry: its impact on psychopharmacological treatment.
    Loga S; Loga-Zec S
    Psychiatr Danub; 2009 Sep; 21(3):347-9. PubMed ID: 19794354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Behavior problems in adults with mental retardation. Psychopharmaceuticals are used too often--pedagogical efforts would be better].
    Näslund I
    Lakartidningen; 2007 Apr 4-17; 104(14-15):1132-5. PubMed ID: 17472101
    [No Abstract]   [Full Text] [Related]  

  • 36. [Status of and perspectives on psychiatric genomic medicine].
    Mors NP; Børglum AD
    Ugeskr Laeger; 2005 May; 167(20):2191-3. PubMed ID: 15987082
    [No Abstract]   [Full Text] [Related]  

  • 37. [Unwanted effects of psychotropic drugs--selected results from a 10-year multicenter project monitoring drugs in psychiatry].
    Grohmann R; Schmidt LG; Antretter K; Rüther E
    Internist (Berl); 1990 Jul; 31(7):468-74. PubMed ID: 1975570
    [No Abstract]   [Full Text] [Related]  

  • 38. Psychotropics in pregnancy: weighing the risks.
    Grover S; Avasthi A; Sharma Y
    Indian J Med Res; 2006 Apr; 123(4):497-512. PubMed ID: 16783040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rating scales to measure adverse effects of medications in people with intellectual disability: a scoping review.
    Kelly N; Kilmartin A; Lannon K; Lee C; McLoughlin R; Mulvanny L; Mohamed O; Treacy M; Rossi K; O'Connell J
    Eur J Clin Pharmacol; 2022 Nov; 78(11):1711-1725. PubMed ID: 36042024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The current extent of biological therapy of mental disorders. I].
    Predescu V; Alexandrescu L; Ciurez T
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1980; 25(3):161-83. PubMed ID: 6110231
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.